The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The grant will fund preclinical studies of the dCK inhibitor TRE-515 with KRAS inhibitors in mice, which will then inform the design of clinical trials.

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.

The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.

The company plans to launch a Phase I trial of its lead autologous cell therapy for renal cell carcinoma in 2026.

The nonprofit subsidiary Orphan Therapies will be the exclusive commercializaiton partner for the Wiskott-Aldrich syndrome gene therapy in the US.

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...